Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis

J Surg Res. 2009 Dec;157(2):235-42. doi: 10.1016/j.jss.2008.08.035. Epub 2008 Sep 29.

Abstract

Background: Immune function after hemorrhagic shock and subsequent sepsis is characterized by an early proinflammatory burst of IL-6, and high IL-6 levels have been linked to high mortality after trauma and in sepsis. Trans-signaling is defined as the activation of cells that do not express the membrane bound IL-6 receptor by the complex of IL-6 and the soluble IL-6 receptor (sIL-6R). Gp130-Fc is able to bind the IL-6/sIL-6R complex, and beneficial effects of IL-6 blockade in chronic inflammatory diseases have been shown. The first aim of this study was to investigate the potential effect of a gp130 blockade via the gp130-Fc antibody causing impairment of IL-6 signaling. The second aim was to find out what role the IL-6/sIL-6R complex can play in the context of hemorrhagic shock and subsequent sepsis as an acute inflammatory disease.

Material and methods: Male CBA/J mice were subjected to hemorrhagic shock (35+/-5 mmHg for 90min and fluid resuscitation) or sham operation. At resuscitation each animal received either 0.5mg gp130-Fc or placebo (PL) i.p. At 48 h after resuscitation, both splenocytes and peritoneal macrophages (pMphi) were harvested or polymicrobial sepsis was induced by cecal ligation and puncture. Survival over 10 d was determined. Release of IL-6, TNF-alpha, and IL-10 of pMphi and release of IL-2, IL-10, and IFN-gamma of splenocytes was assessed by ELISA. Proliferation of splenocytes and their morphologic damage were determined.

Results: Binding of the IL-6/sIL-6R complex by gp130-Fc led to significant lower IL-6 levels compared with placebo treated animals. Placebo treated males showed depressed proinflammatory immune response (IL-2, IL-6) after hemorrhagic shock. While splenocyte proliferation was significantly reduced directly after hemorrhagic shock and restored after 48 h by gp130-Fc, pMphi cytokine release was not influenced. Finally, survival appeared to be unaffected.

Conclusion: Transsignaling does not seem to play a pivotal role in the development of the immune dysfunction and mortality in our model of hemorrhage and subsequent sepsis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / pharmacology*
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Cytokine Receptor gp130 / antagonists & inhibitors
  • Cytokine Receptor gp130 / immunology*
  • Cytokine Receptor gp130 / metabolism
  • Disease Models, Animal
  • Ileum / pathology
  • Immune System / drug effects
  • Immune System / physiology
  • Interleukin-6 / antagonists & inhibitors*
  • Interleukin-6 / metabolism
  • Kidney / pathology
  • Liver / pathology
  • Lung / pathology
  • Macrophages, Peritoneal / metabolism
  • Male
  • Mice
  • Mice, Inbred CBA
  • Monokines / metabolism
  • Receptors, Interleukin-6 / antagonists & inhibitors*
  • Receptors, Interleukin-6 / metabolism
  • Sepsis / immunology
  • Sepsis / metabolism*
  • Sepsis / pathology
  • Shock, Hemorrhagic / immunology
  • Shock, Hemorrhagic / metabolism*
  • Shock, Hemorrhagic / pathology
  • Signal Transduction / drug effects*
  • Signal Transduction / physiology
  • Spleen / drug effects
  • Spleen / metabolism
  • Spleen / pathology

Substances

  • Antibodies
  • Interleukin-6
  • Monokines
  • Receptors, Interleukin-6
  • Cytokine Receptor gp130